Key facts
- It has raised $14.0M; the latest was Later Stage VC in Dec 2025.
- Notable investors include Lianyungang Jinhai Venture Capital, Lianyungang International Logistics Park Investment, Beijing Shengshi Hongming Investment Fund Management, Jiangsu Jinqiao Private Equity Fund Management.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Qianren Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Qianren Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Qianren Pharmaceuticals
Developer of integrative emerging pharmaceuticals designed for the treatment of chronic and oncological diseases. The company specializes in the research, development and production of drugs, which are mainly used to treat cardiovascular and cerebrovascular diseases, digestive system diseases, as well as drugs for skeletal muscle pain relief, anti-tumor and diabetes.
- Sector
- Healthcare
- HQ
- Lianyungang, China
- Founded
- 2016
- Website
- qianrenpharm.com/
- Ownership
- Privately Held (backing)
Qianren Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Qianren Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Qianren Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.